Log in

LON:INDVIndivior Share Price, Forecast & News

GBX 86.45
+1.40 (+1.65 %)
(As of 07/10/2020 04:00 PM ET)
Today's Range
Now: GBX 86.45
50-Day Range
MA: GBX 71.81
52-Week Range
Now: GBX 86.45
Volume1.74 million shs
Average Volume2.44 million shs
Market Capitalization£633.19 million
P/E RatioN/A
Dividend YieldN/A
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, opiate overdose, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Read More
Indivior logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.88 out of 5 stars

Industry, Sector and Symbol

Industry Drugs - Generic



Sales & Book Value

Annual Sales£700 million
Cash FlowGBX 128.74 per share
Book ValueGBX 5.30 per share



Market Cap£633.19 million
Next Earnings Date7/29/2020 (Estimated)
OptionableNot Optionable

Receive INDV News and Ratings via Email

Sign-up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter.

Indivior (LON:INDV) Frequently Asked Questions

How has Indivior's stock been impacted by COVID-19 (Coronavirus)?

Indivior's stock was trading at GBX 46.21 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, INDV stock has increased by 87.1% and is now trading at GBX 86.45. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Indivior?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Indivior in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Indivior.

When is Indivior's next earnings date?

Indivior is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Indivior.

What price target have analysts set for INDV?

2 brokers have issued 12-month target prices for Indivior's shares. Their forecasts range from GBX 45 to GBX 70. On average, they anticipate Indivior's stock price to reach GBX 57.50 in the next twelve months. This suggests that the stock has a possible downside of 33.5%. View analysts' price targets for Indivior.

Has Indivior been receiving favorable news coverage?

Press coverage about INDV stock has trended neutral on Sunday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Indivior earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned media headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Indivior.

Who are some of Indivior's key competitors?

What other stocks do shareholders of Indivior own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Indivior investors own include Futura Medical (FUM), Bigblu Broadband (BBB), Directa Plus (DCTA), Lakehouse (LAKE), Aquila Services Group (AQSG), Benchmark (BMK), Bodycote (BOY), CityFibre Infrastructure (CITY), Deltex Medical Group (DEMG) and Kingfisher (KGF).

Who are Indivior's key executives?

Indivior's management team includes the following people:
  • Mr. Shaun Thaxter, CEO & Exec. Director
  • Mr. Mark Crossley, CFO & Exec. Director
  • Dr. Christian Heidbreder, Chief Scientific Officer
  • Mr. Ingo Elfering, Chief Information & Innovation Officer
  • Mr. Jason Thompson, VP of Investor Relations

What is Indivior's stock symbol?

Indivior trades on the London Stock Exchange (LON) under the ticker symbol "INDV."

How do I buy shares of Indivior?

Shares of INDV and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Indivior's stock price today?

One share of INDV stock can currently be purchased for approximately GBX 86.45.

How big of a company is Indivior?

Indivior has a market capitalization of £633.19 million and generates £700 million in revenue each year. Indivior employs 915 workers across the globe.

What is Indivior's official website?

The official website for Indivior is indivior.com.

How can I contact Indivior?

Indivior's mailing address is 103-105 Bath Road, SLOUGH, SL1 3UH, United Kingdom. The specialty pharmaceutical company can be reached via phone at +44-1753-217800.

This page was last updated on 7/12/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.